Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Biogen (BIIB) 10K Form and Latest SEC Filings 2026

Biogen logo
$187.80 -2.76 (-1.45%)
Closing price 04:00 PM Eastern
Extended Trading
$187.75 -0.05 (-0.03%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Biogen SEC Filings & Recent Activity

Biogen (NASDAQ:BIIB) has submitted 532+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Biogen's financial statements. The most recent filing was a Form SCHEDULE 13D/A submitted on May 14, 2026.

Form 4
BIOGEN INC. Reports Ownership Change on Apr. 3, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Biogen Files Current Report on May. 14, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Biogen Files Quarterly Report on Apr. 29, 2026

The 10-Q contains Biogen's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Biogen SEC Filing History

Browse Biogen's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/14/2026 3:36 PM
Apellis Pharmaceuticals, Inc. (1492422) Subject
Biogen (875045) Filed by
Form SCHEDULE 13D/A
05/14/2026 7:31 AM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2026 6:53 AM
Apellis Pharmaceuticals, Inc. (1492422) Subject
Biogen (875045) Filed by
Form SC TO-T/A
05/12/2026 6:06 AM
Apellis Pharmaceuticals, Inc. (1492422) Subject
Biogen (875045) Filed by
Form SC TO-T/A
05/06/2026 10:00 AM
Biogen (875045) Subject
FMR LLC (315066) Filed by
Form SCHEDULE 13G/A
04/29/2026 4:00 PM
Biogen (875045) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/29/2026 5:40 AM
Biogen (875045) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2026 5:05 AM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/28/2026 3:42 PM
Biogen (875045) Filer
Form DEFA14A
04/28/2026 3:47 PM
Biogen (875045) Filer
Form ARS
04/28/2026 3:34 PM
Biogen (875045) Filer
Form DEF 14A
04/14/2026 6:02 AM
Apellis Pharmaceuticals, Inc. (1492422) Subject
Biogen (875045) Filed by
Form SC TO-T
04/07/2026 4:05 PM
Apellis Pharmaceuticals, Inc. (1492422) Subject
Biogen (875045) Filed by
Form SC TO-C
04/06/2026 5:08 PM
Apellis Pharmaceuticals, Inc. (1492422) Subject
Biogen (875045) Filed by
Form SCHEDULE 13D
04/06/2026 5:11 PM
Apellis Pharmaceuticals, Inc. (1492422) Issuer
Biogen (875045) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/06/2026 5:31 AM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/03/2026 4:10 PM
Apellis Pharmaceuticals, Inc. (1492422) Subject
Biogen (875045) Filed by
Form SC TO-C
04/03/2026 3:05 PM
Biogen (875045) Issuer
Godbout Sean (2057736) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 4:01 PM
Apellis Pharmaceuticals, Inc. (1492422) Subject
Biogen (875045) Filed by
Form SC TO-C
03/31/2026 4:03 PM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2026 4:08 PM
Apellis Pharmaceuticals, Inc. (1492422) Subject
Biogen (875045) Filed by
Form SC TO-C
03/26/2026 3:09 PM
Biogen (875045) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/11/2026 4:28 PM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 7:10 PM
Biogen (875045) Issuer
Grogan Jane (1995547) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:11 PM
Biogen (875045) Issuer
Izzar Rachid (1875506) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:12 PM
Biogen (875045) Issuer
Keeney Adam (1973607) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:14 PM
Biogen (875045) Issuer
Kramer Robin (1609222) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:16 PM
Biogen (875045) Issuer
Murphy Nicole (1910644) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:17 PM
Biogen (875045) Issuer
Singhal Priya (1769608) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:18 PM
Biogen (875045) Issuer
Viehbacher Christopher (1774478) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:05 PM
ALEXANDER SUSAN H (1263839) Reporting
Biogen (875045) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:07 PM
Biogen (875045) Issuer
Godbout Sean (2057736) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:09 PM
Biogen (875045) Issuer
Gregory Ginger (1545716) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/11/2026 4:07 PM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/10/2026 3:55 PM
ALEXANDER SUSAN H (1263839) Reporting
Biogen (875045) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2026 3:56 PM
Biogen (875045) Issuer
Godbout Sean (2057736) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2026 3:58 PM
Biogen (875045) Issuer
Gregory Ginger (1545716) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2026 3:59 PM
Biogen (875045) Issuer
Grogan Jane (1995547) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2026 4:00 PM
Biogen (875045) Issuer
Izzar Rachid (1875506) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2026 4:01 PM
Biogen (875045) Issuer
Keeney Adam (1973607) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2026 4:02 PM
Biogen (875045) Issuer
Kramer Robin (1609222) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
SpaceX will mint billionaires. You won't be one of them. (Ad)

By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.tc pixel

Get the ticker now before the June S-1 closes the window
02/09/2026 9:14 AM
Biogen (875045) Subject
Singhal Priya (1769608) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/06/2026 6:36 AM
Biogen (875045) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/06/2026 5:55 AM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/05/2026 12:16 PM
Biogen (875045) Subject
FMR LLC (315066) Filed by
Form SCHEDULE 13G
02/02/2026 10:10 AM
Biogen (875045) Subject
Singhal Priya (1769608) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2025 7:28 PM
Biogen (875045) Subject
PRIMECAP MANAGEMENT CO/CA/ (763212) Filed by
Form SCHEDULE 13G/A
11/10/2025 7:15 AM
Biogen (875045) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
10/30/2025 5:31 AM
Biogen (875045) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/30/2025 5:13 AM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/14/2025 3:19 PM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/06/2025 12:00 PM
Biogen (875045) Issuer
Godbout Sean (2057736) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2025 4:56 PM
Biogen (875045) Issuer
Singhal Priya (1769608) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2025 11:54 AM
Biogen (875045) Subject
Singhal Priya (1769608) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/31/2025 5:05 AM
Biogen (875045) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/31/2025 5:13 AM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/30/2025 4:56 PM
Biogen (875045) Filed by
Sage Therapeutics, Inc. (1597553) Subject
Form SCHEDULE 13D/A
07/21/2025 8:18 PM
Biogen (875045) Filed by
Sage Therapeutics, Inc. (1597553) Subject
Form SCHEDULE 13D/A
07/16/2025 4:55 PM
Biogen (875045) Issuer
Izzar Rachid (1875506) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/08/2025 2:26 PM
Biogen (875045) Subject
Izzar Rachid (1875506) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/07/2025 3:10 PM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/23/2025 3:18 PM
Biogen (875045) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/18/2025 3:42 PM
Biogen (875045) Issuer
SHERWIN STEPHEN A (1079462) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 3:44 PM
Biogen (875045) Issuer
Rowinsky Eric K (1318886) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 3:45 PM
Biogen (875045) Issuer
Freire Maria C (1547999) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 3:46 PM
Biogen (875045) Issuer
HAWKINS WILLIAM A (1106508) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 3:47 PM
Biogen (875045) Issuer
Mantas Jesus B (1777331) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 3:53 PM
Biogen (875045) Issuer
Patolawala Monish D (1815253) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 3:34 PM
Biogen (875045) Issuer
DORSA CAROLINE (1181174) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 3:38 PM
Biogen (875045) Issuer
LANGER SUSAN (1982640) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2025 8:20 AM
Biogen (875045) Filer
Form DEFA14A
(Data available from 1/1/2016 forward)

Biogen SEC Filings - Frequently Asked Questions

Biogen (BIIB) has submitted 532+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Biogen's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Biogen's financial statements page.

The most recent filing was a Form SCHEDULE 13D/A submitted on May 14, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:BIIB) was last updated on 5/20/2026 by MarketBeat.com Staff.
From Our Partners